News Update (July 24, 2025)
Spinal cord injury patients respond well to novel treatment.
We are excited to announce that Dr. Dabrowski successfully treated a group of 9 SCI patients with oral xanthohumol. This clinical study continues (see Treatment of Spinal Cord Injury in this website for preliminary details).
This is the unprecedented medical progress where effective treatment developed in the model of devastating human disease resulted in the optimal dose, translated to humans, resulted in remarkable recovery of all treated SCI patients.
The development of VPCnt-101, the lead treatment by VPC NeuroTherapeutics Inc., based on synthesized xanthohumol is progressing towards regulatory approvals and clinical trials.
New Book
We are excited to announce the publication of a monograph explaining the pathogenesis of neurotrauma and stroke in the rat model of the SCI. It also discusses neuroprotective and neuroregenerative treatments tested in the rat models.
Kwiecien JM. “Treatment Of Inflammation Initiated By The Spinal Cord Injury, The Brain Injury, Stroke, In Inhibition Of Cerebral And Spinal Cord Edema And Of Inflammation In Neurodegenerative, Immune Mediated And Infectious Diseases Of The Central Nervous System”. USPTO Patent US20220395474A1, December 15, 2022.
